Similarly, another study highlighted that promoter methylation of at least one of the six genes in the panel (BRCA1, p16ink4a, APC, p14arf, RASSF1A, and DAPK) could efficiently differentiate patients with ovarian cancer from healthy control with 99% (70/71) sensitivity and 100% specificity, utilizing multiplex methylation-specific PCR (MS-PCR) (de Caceres et al., 2004). This evidence concerns the gene CDKN2A and ovarian cancer.